Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
  2. Our Websites |
  3. Global Business Webistes |
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
Empowering Life

Welcome to
Sanofi India Limited


    Content :

    Welcome to Sanofi India Limited in India

    Welcome to our website. We would like to give you an overview of Sanofi India Limited in India: our background, organisation, products as well as financial information.

    Contact us

    Sanofi India Limited

    Sanofi House,
    CTS No.117-B, L&T Business Park,
    Saki Vihar Road, Powai,
    Mumbai 400072

    Tel no. (022) 28032000
    Fax no.(022) 28032846

    Latest News

    September 18, 2018

    26 young people with type 1 diabetes successfully surmount 13,000 ft., in ‘India’s 2nd T1D Challenge 2018’


    Pharmacovigilance / Medical Information

    All consumers or patients are advised to contact their doctor or healthcare professional for advice on medicines or any health matters/medical emergencies.

    Pharmacovigilance remains a key activity in the assessment of the therapeutic value of products. Sanofi ensures continuous monitoring and management of the safety profile of all its products through its drug safety data collection worldwide.
    For reporting adverse events, please send an email to PV.india@sanofi.com

    A key activity of Sanofi is to provide updated medical information in compliance with Indian regulations, on its products, to healthcare professionals.
    For medical information, please send your queries to medinfo.india@sanofi.com

    You can also call us between 9AM and 5PM on any working day* at 022-28032000. Please select IVRS option 2 for medical information and IVRS option 3 for reporting adverse events.

    *Please note that we are closed on Saturday, Sunday and Public Holidays.

    Latest Financial Results

    Clarifications issued by the Company